Oncomir MicroRNA-346 Is Upregulated in Colons of Patients With Primary Sclerosing Cholangitis.


Journal

Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 24 1 2020
medline: 20 11 2020
entrez: 24 1 2020
Statut: ppublish

Résumé

Primary sclerosing cholangitis (PSC) is a cholestatic liver disorder that is frequently associated with ulcerative colitis (UC). Patients with PSC and UC (PSC-UC) have a higher risk of colorectal neoplasia compared with patients with UC. The oncogenic properties of microRNA-346 (miR-346) have been recently reported. We investigated the expression of miR-346 and its 2 target genes, the receptor of vitamin D (VDR), and the tumor necrosis factor-α (TNF-α), which are known to modulate carcinogenesis. Ascending and sigmoid colon biopsies were obtained from patients with PSC, PSC and UC (PSC-UC), UC, and healthy controls (n = 10 in each group). Expressions of VDR, TNF-α, 18S RNA, p27, miR-346, and reference microRNA, miR-191, were evaluated by real-time PCR using human TaqMan Gene Expression and TaqMan MicroRNA Assays. Functional studies with miR-346 mimic and inhibitor were conducted in HepG2 and Caco-2 cells. The effect of ursodeoxycholic acid on miR-346 expression was examined in Caco-2 cells. An increased expression of miR-346 in the ascending colon of PSC-UC was observed (P < 0.001 vs all groups). In patients with UC, an exceptionally low colonic expression of miRNA-346 was accompanied by the extensive upregulation of VDR and TNF-α genes. A functional in vitro analysis demonstrated that inhibition of miR-346 resulted in the upregulation of VDR and TNF-α, whereas the induction of miR-346 activity suppressed VDR, TNF-α, and p27. The upregulation of miRNA-346 in the colon of patients with PSC may be responsible for the disturbance of VDR and TNF-α signaling pathway, which could result in an inadequate suppression of neoplasia.

Identifiants

pubmed: 31972611
doi: 10.14309/ctg.0000000000000112
pmc: PMC7056054
pii: 01720094-202001000-00006
doi:

Substances chimiques

Cholagogues and Choleretics 0
MIRN346 microRNA, human 0
MicroRNAs 0
RNA, Ribosomal, 18S 0
Receptors, Calcitriol 0
TNF protein, human 0
Tumor Necrosis Factor-alpha 0
VDR protein, human 0
Cyclin-Dependent Kinase Inhibitor p27 147604-94-2
Ursodeoxycholic Acid 724L30Y2QR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00112

Références

Lancet. 2013 Nov 9;382(9904):1587-99
pubmed: 23810223
Gastroenterology. 1993 Jan;104(1):145-51
pubmed: 8419237
Int J Mol Sci. 2017 Jan 29;18(2):
pubmed: 28146070
Gut. 2001 Apr;48(4):526-35
pubmed: 11247898
J Clin Invest. 2013 Sep;123(9):3983-96
pubmed: 23945234
Am J Pathol. 1992 Mar;140(3):539-44
pubmed: 1372154
J Steroid Biochem Mol Biol. 2015 Apr;148:179-83
pubmed: 25603468
Biomed Pharmacother. 2016 Dec;84:705-713
pubmed: 27701052
World J Gastroenterol. 2015 Nov 21;21(43):12274-82
pubmed: 26604636
Calcif Tissue Int. 2013 Feb;92(2):77-98
pubmed: 22782502
Tumour Biol. 2016 Feb;37(2):2765-71
pubmed: 26408183
Prostate Cancer. 2012;2012:128965
pubmed: 23326670
Cell Cycle. 2009 Mar 1;8(5):736-41
pubmed: 19221487
Oncotarget. 2016 Sep 27;7(39):64371-64379
pubmed: 27608842
Nat Med. 1997 Feb;3(2):231-4
pubmed: 9018245
Gene. 2017 Feb 5;600:21-28
pubmed: 27913185
Am J Gastroenterol. 1997 Aug;92(8):1285-8
pubmed: 9260790
Nat Rev Cancer. 2014 May;14(5):342-57
pubmed: 24705652
Oncol Lett. 2017 Sep;14(3):3255-3260
pubmed: 28927074
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):110-7
pubmed: 20134493
Mutat Res. 2005 Jan;589(1):47-65
pubmed: 15652226
Oncology. 2000;58(1):45-51
pubmed: 10644940
PLoS One. 2011;6(5):e19827
pubmed: 21611196
FASEB J. 2016 Mar;30(3):1367-76
pubmed: 26700731
PLoS One. 2010 Oct 05;5(10):
pubmed: 20957151
Int J Mol Sci. 2017 Nov 07;18(11):
pubmed: 29112157
Inflamm Bowel Dis. 2014 Nov;20(11):1910-8
pubmed: 25192497
J Clin Lab Anal. 1999;13(6):291-5
pubmed: 10633297
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G208-16
pubmed: 17962355
Front Immunol. 2017 Jan 20;7:697
pubmed: 28163705
Scand J Gastroenterol. 2007 Nov;42(11):1312-20
pubmed: 17852866
J Hepatol. 2009 Jan;50(1):158-64
pubmed: 19012991
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
Cancers (Basel). 2018 Jan 20;10(1):
pubmed: 29361689
Inflamm Bowel Dis. 2009 Sep;15(9):1331-6
pubmed: 19229982
Int J Cancer. 2016 Mar 1;138(5):1118-28
pubmed: 26413860
Immunol Rev. 2004 Dec;202:275-93
pubmed: 15546400

Auteurs

Agnieszka Kempinska-Podhorodecka (A)

Department of Medical Biology, Pomeranian Medical University, Szczecin, Poland.

Malgorzata Blatkiewicz (M)

Department of Medical Biology, Pomeranian Medical University, Szczecin, Poland.

Ewa Wunsch (E)

Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.

Lukasz Krupa (L)

Department of Gastroenterology, Teaching Hospital No 1, Rzeszow, Poland.

Krzysztof Gutkowski (K)

Department of Gastroenterology, Teaching Hospital No 1, Rzeszow, Poland.

Piotr Milkiewicz (P)

Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.
Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.

Malgorzata Milkiewicz (M)

Department of Medical Biology, Pomeranian Medical University, Szczecin, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH